Summit Therapeutics (SMMT) Misses Q4 EPS by 21c

Summit Therapeutics (NASDAQ: SMMT) reported Q4 EPS of (GBP0.29), GBP0.21 worse than the analyst estimate of (GBP0.08).

For earnings history and earnings-related data on Summit Therapeutics (SMMT) click here.

You May Also Be Interested In

• Summit Therapeutics plc (SMMT) PT Raised to $9.80 at Bernstein SocGen Group
• ZenaTech raises Plurilock Security stake to 12% with new share purchase
• Boeing wins $121 million Navy contract for P-8A upgrades